Taysha Gene Therapies Net Change in Investments - Total 2020-2025 | TSHA

Taysha Gene Therapies net change in investments - total from 2020 to 2025. Net change in investments - total can be defined as the total change in long term and short term investments
Taysha Gene Therapies Annual Net Change in Investments - Total
(Millions of US $)
2024 $N/A
2023 $N/A
2022 $N/A
2021 $N/A
2020 $N/A
2019 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.599B $0.008B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.298B 6.98
Dr Reddy's Laboratories (RDY) India $12.071B 21.91
BridgeBio Pharma (BBIO) United States $6.397B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.850B 15.02
Bausch Health Cos (BHC) Canada $1.681B 1.24
Amphastar Pharmaceuticals (AMPH) United States $1.178B 7.84
Personalis (PSNL) United States $0.443B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.021B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00